A dysregulated inflammation is typical of the CF lung disease and new therapies aimed at its reduction could lead to a substantial improvement in the disease. Anakinra (Kineret) is a drug that can be subcutaneously administered, already on the market for other human inflammatory pathologies; it has also passed the stages of preclinical research in the CF field and it is currently being tested in CF patients through a phase II clinical trial, with subcutaneous administration (EudraCT No: 2016-004786-80). The possibility of administering it either orally or by aerosol would favor greater patients’ compliance, helping to overcome the burden of chronic poly-therapies in CF. Hence, with this project researchers will develop formulations of anakinra to be orally administered or delivered by aerosol. They will prepare both enteric microparticles and dry inhalable anakinra powders and will evaluate their activity in primary CF bronchial cells and in CF mouse models. The prospect is that these new formulations can quickly be transferred into clinical use thus facilitating the anakinra’s repurposing in CF.